

## Quarterly Update

January 30, 2026

Australian internet of things (IoT) and healthcare technology company, Oakridge International Limited (ASX: OAK) (“Oakridge” or the “Company”), is pleased to provide the following business update alongside its Appendix 4C Quarterly Cash Flow Report for the quarter ended 31 December 2025 (the “Period”).

The Company is a provider of innovative technology solutions for the healthcare sector where it develops and distributes its own range of nurse call and assistive technology hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

### Key Highlights

- The Company continued to deliver a solid performance for the Period, supported by growing revenue, consistent customer orders, additional investment in inventory to meet upcoming demand, disciplined cost control and ongoing progress across its healthcare technology operations. Group performance for the half year reflects a significant improvement on the prior corresponding period, underpinned by growing healthcare revenues and the contribution of R&D grant income.
- Receipts from customers for the Period were A\$619,000, contributing to A\$1.204 million in operating cash receipts for the six months to 31 December 2025.
- Payments for product manufacturing and operating costs, staff, administration and corporate costs remained in line with expectations.
- Increased investment in inventory to support customer orders and anticipated demand.
- RTLS enablement for the core platform has been completed, with initial production hardware scheduled to arrive in early 2026 to fulfil significant committed orders.
- Strategic partner relationships continued to strengthen across all states, with ongoing distribution discussions aimed at supporting broader national coverage

### Business Development and Industry Engagement

- Partner activity remained strong across aged care, retirement and hospital projects, with active engagements involving Wireless and RTLS solutions, nurse call upgrades and multisite rollouts.
- The project pipeline includes both partner and direct opportunities in Australian healthcare and selected international markets, with several larger projects in late negotiation or awaiting purchase orders.
- Management expects these channel and project activities to support increased revenue over the balance of FY2026.

### **Sales and Projects**

- Project activity remained solid through the Period, with ongoing delivery and a qualified pipeline continuing to support future revenue growth.
- The project pipeline at December 2025 comprised a substantial mix of contracted work still to be invoiced and new opportunities across partners and direct customers, providing a strong foundation for future revenue.
- Installations progressed across a number of key sites, with systems moving from deployment into active operation in staged phases.
- Work with major property and care providers advanced across several concurrent projects, maintaining continuity of workload.
- Assisted living programs were further expanded, with new NuCaMS, based integrated solutions implemented in additional locations.

### **Product and Technology Development**

- RTLS development remains on schedule, with call points, staff and resident tags, firmware and associated tooling progressing toward first production shipments from early 2026.
- NuCaMS Enterprise development advanced further, with core infrastructure and Single Sign On (SSO) integration substantially complete and enterprise reporting modules targeted for delivery in Q1 2026.
- Software development included completion of integration for transition solutions in supported living environments and ongoing validation of hardware options for sign in/out and related workflow tools.
- Product planning continues to track the evolving AS83112024 nurse call standard to ensure compliance and preserve competitive positioning across new deployments.

### **Human Resources and Operations**

- Project rostering and resource allocation are being optimised, balancing workloads during key project and product development, while accommodating planned leave schedules.
- Internal communications, system use and data consistency continue to benefit better aligning operations more closely with financial control.

### **Marketing and Industry Engagement**

- Brand visibility continued to build, supported by ongoing digital activity and partner campaigns. Engagement across social channels led to more inbound enquiries and qualified project leads in the healthcare sector.

### **Related Party Payments**

During the reporting period, related party payments totaling \$8,000 were made. These payments pertain to Director and Executive Officer fees.

### **Other Matters**

As announced on 2 January 2020, the Company completed a A\$250,000 share placement (“Placement Agreement”) with Teko International Limited (Teko).

On 28 July 2020, the Company held a discussion with Teko in respect to a potential claim asserted by Teko against the Company for allegedly misrepresenting the Company’s unrecorded liabilities, including the Heuresy liability payment previously disclosed, by its then directors.

The Board believes that there may be some exposure to the Company in respect to the representations made by the then Board members. If the Company were to be subject to legal action that could be taken by Teko, there could be no assurance as to the outcome or the costs required to defend any such action.

The Company will continue to discuss the issue with our legal advisors and negotiate with Teko to seek the most desirable outcome for the Company and its shareholders.

### **Overall Outlook**

Overall, management believes the Group is well positioned to continue operations and deliver on its business objectives, supported by its healthcare technology pipeline, product development program and improving financial performance.

This shareholder update has been approved by the Board of Oakridge International Limited.

Julie Edwards  
Company Secretary  
Oakridge International Limited

For further information, please contact: Oakridge International Limited (ASX: OAK)  
P: +61 8 8223 0200. E: [info@oakridgeint.com](mailto:info@oakridgeint.com)

### **Forward-looking statements**

This announcement contains or may contain forward-looking statements that are based on Oakridge’s beliefs, assumptions and expectations and on information currently available to Oakridge. All statements that address operating performance, events or developments that Oakridge or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Oakridge or the market it operates in.

Oakridge believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Oakridge does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to and no reliance should be placed on, the future business performance or results of Oakridge or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oakridge International Limited

**ABN**

89 122 203 196

**Quarter ended ("current quarter")**

31 December 2025

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	619	1,204
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(583)	(806)
(c) advertising and marketing	(9)	(20)
(d) leased assets	-	-
(e) staff costs	(258)	(554)
(f) administration and corporate costs	(205)	(304)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(1)	(3)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(437)</b>	<b>(483)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	115	215
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payments for lease liabilities)	(26)	(52)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>89</b>	<b>163</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	499	471
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(437)	(483)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	89	163
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>151</b>	<b>151</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	151	499
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>151</b>	<b>499</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	8
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(437)
8.2 Cash and cash equivalents at quarter end (item 4.6)	151
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	151
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	0.35
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: The Company expects net operating cash flows to increase over the next two quarters, reflecting recent investment in inventory, the collection of receivables and a growing pipeline of customer orders and enquiries.	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: The Company is evaluating the options available and believe that it is likely that additional funds will be obtained.	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: The Company believes it will be able to continue its operations and meet its business objectives, supported by an expected uplift in cashflow in the next quarter. This anticipated improvement is underpinned by inventory investment made during the current period, the collection of existing receivables, a solid pipeline of customer orders and a growing level of new enquiries across its core markets.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

30 January 2026

Date: .....

The Board

Authorised by: .....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.